A Critical Review of Outcomes of Cancer during the COVID-19 Pandemic

Abstract
The recent outbreak of COVID-19 has created an alarming fear, apprehension, and worry world over. Cancer patients represent a subgroup that is vulnerable and is under high risk. It is, therefore, necessary to analyze factors that predict outcomes in these patients so that they can be triaged accordingly in order to mitigate the effects of COVID-19 on cancer management. To determine the factors affecting cancer patients in COVID-19. A systematic search was performed to identify all relevant studies on PubMed, Embase, and Google Scholar published until April 5, 2020. Relevant articles that reported the incidence, demographic and clinical characteristics, treatment, and outcomes of cancer patients infected by COVID-19 were included in the analysis. Among 559 articles that were further screened, 14 articles fulfilled the inclusion criteria. The incidence of cancer across various studies ranged from 0.5% to 2.43%. Males were more than females, and the mean age affected was 63.1–66 years. Lung cancer was the most common subtype (25%–58.3%). Cancer patients, as reported, had a higher risk of progressing to severe events (hazard ratio: 3.56, 95% confidence interval: 1.65–7.69; \( P < 0.0001 \)). Nearly 39%–53.6% of patients who had a recent history of anticancer therapy developed severe events. Individuals with cancer feared the risk of complications. Cancer patients have worse outcomes from COVID-19, compared to the general population, providing a reason to pay more timely attention. High-risk patients should have vigorous screening and intensive surveillance. Anticancer treatment during COVID-19 should be modified based on the type and prognosis of cancer.

Keywords: Cancer, COVID-19, malignancy, severe acute respiratory syndrome-related coronavirus

Introduction
Severe acute respiratory syndrome-related coronaviruses (SARS-CoVs) are single-stranded, positive-sense, nonsegmented, enveloped RNA viruses. In the past, the world has seen three other “novel” CoV outbreaks that caused substantial destruction. The recent outbreak of COVID-19 has created an alarming fear, apprehension, and worry world over. With the number of confirmed cases on the rise, governments and health-care workers are faced with the challenge of curbing its spread and the resultant damage.

The first pandemic of the 21st century was caused by the SARS-CoV-1.[1] It presented as atypical pneumonia in the latter half of 2002[2,3] in Foshan, Guangdong Province, mainland China, from where it spread to Hong Kong,[4] Vietnam, Canada, and Singapore.[5] The epidemic lasted about a year infecting over 8000 individuals and resulting in 774 deaths with a case fatality rate of 9.5%.[6]

A decade later, another CoV emerged in the Middle East called the Middle East respiratory syndrome-CoV (MERS-CoV). MERS-CoV was a zoonotic virus that entered into the human lineage from dromedary camels in the Arabian Peninsula.[7] In comparison to SARS-CoV, MERS-CoV had a much higher case fatality rate of around 35% but it has allowed control due to low R0 (basic reproduction number).[8] It claimed around 858 lives with 2494 laboratory-confirmed cases.

In December 2019, reports emerged of a cluster of cases in Wuhan, China, ailing with pneumonia of unknown etiology. In the following week, a strain of CoV was isolated from these patients. It was initially referred to as novel CoV 2019 but was officially named by the World Health Organization (WHO) on 11 February 2020 as COVID19. The incubation period of the virus ranges from 2 to 14 days (median 5 days). Angiotensin-converting enzyme-2 (ACE2) has been found as the receptor through which the virus invades the respiratory mucosa.[8]
In the last century, the world has faced pandemics such as the plague; smallpox; cholera; yellow fever; and Spanish-, Russian-, Hong Kong- and Asian-flu that claimed millions of lives. The H1N1 swine flu pandemic which originated in Mexico in 2009 spread across the rest of the world infecting roughly 1.4 billion people and killing between 151,700 and 575,400 according to the Centers for Disease Control and Prevention (CDC). Ebola spread across Guinea, Liberia, and Sierra Leone between 2014 and 2016 reporting 28,610 cases and 11,308 deaths.

Cancer patients receive special consideration as they represent a subgroup that is immunocompromised and is under high risk. While coping up with the fears associated with the diagnosis of cancer, the COVID-19 pandemic places another hurdle in their path. It is, therefore, necessary to analyze factors that predict outcomes in these patients so that they can be treated effectively.

**Methodology**

A systematic search was performed to identify all relevant studies on PubMed, Embase, and Google Scholar published until April 5, 2020, as per the PRISMA guidelines. The following MESH terms were used: Beta coronavirus or severe acute respiratory syndrome coronavirus 2 or COVID-19 or Coronavirus Infections or Coronavirus and Neoplasms or Cancer Care Facilities or Cancer Survivors or Radiation Oncology or Drug Therapy or Chemotherapy, Adjunct or Chemotherapy, Cancer, Regional Perfusion or Induction Chemotherapy or Maintenance Chemotherapy. Additional searches were done from reference lists of included studies to avoid any missing articles.

Relevant articles that reported the incidence, demographic and clinical characteristics, treatment, and outcomes of cancer patients infected by COVID-19 were included in the analysis. Articles were graded as per the level of evidence they reported using the Oxford Centre for Evidence-Based Medicine system. The search resulted in 559 articles that were further screened according to the inclusion and exclusion criteria. Articles based on influenza and SARS were excluded, which resulted in 14 articles which were dealt with cancer during the COVID-19 pandemic, however demographic data were available only in three studies. As the sample size was less with limited data available from the quoted studies, statistical analysis was not done.

**Results**

The search resulted in 559 articles that were further screened by the authors. Out of these, 14 articles fulfilled the inclusion criteria.

**Demographics**

The demographic details about the cancer patients in various studies are tabulated in Table 1.

A nationwide analysis in China by Liang et al.\(^{[10]}\) found that cancer patients were of advanced age and more likely to be associated with a history of smoking, severe baseline computed tomography (CT) manifestation, and a higher risk of progressing to severe events (hazard ratio [HR]: 3.56, 95% confidence interval [CI] [1.65–7.69]; \(P < 0.0001\)).

The most common symptom on admission in Zhang et al.’s study was fever (\(n = 23, 82.1\%\)), followed by cough (\(n = 22, 81\%\)) and fatigue (\(n = 18, 64.3\%\)). Blood parameters were suggestive of anemia in 21 (75\%), lymphopenia in 23 (82.1\%), and leukopenia in 9 (32.1\%) patients. Levels of albumin were on the lower side in 25 (89.3\%) patients, and 92.9\% of the patients had normal prolactin levels. Levels of serum globulin (11 [39.3\%]), lactate dehydrogenase (10 [50\%]), C-reactive protein levels (23 [82.1\%]), erythrocyte sedimentation rate (16 [57.1\%]), and D-Dimer (11 [39.3\%]) were found to be elevated. Chest CT on admission was abnormal in the entire cohort.

Higher dose of corticosteroids was administered for longer duration in patients with severe events, but it failed to demonstrate any statistically significant difference (dose [mg/kg/day]: 1.0 vs. 0.6, period [day]: 3.0 [2.0–4.8] vs. 5.0).

A significant number of severe cases required mechanical ventilation (noninvasive: 53.3\% vs. 0\%, \(P < 0.001\)) as compared to nonsevere intensive care unit (ICU) cases (noninvasive: 13.3\% vs. 0\%, \(P < 0.001\)). The median period of mechanical ventilation for noninvasive ventilation was 2.5 days (1.0–5.0 days) and 2.5 days for invasive cases.

**Table 1: Demographic distribution of COVID-19-positive cancer patients**

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Zhang et al.(^{[9]}) n (%)</th>
<th>Liang et al.(^{[10]}) n (%)</th>
<th>Yu et al.(^{[11]}) n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>28</td>
<td>18</td>
<td>12</td>
</tr>
<tr>
<td>Male:female</td>
<td>17 (60.7): 11 (39.28)</td>
<td>12 (66.7): 6 (33.3)</td>
<td>10 (83.33): 2 (16.7)</td>
</tr>
<tr>
<td>Mean age (years)</td>
<td>65</td>
<td>63.1</td>
<td>66</td>
</tr>
<tr>
<td>Comorbidity</td>
<td>11 (39.28)</td>
<td>22.2%</td>
<td>-</td>
</tr>
<tr>
<td>Diabetes</td>
<td>4 (14.3)</td>
<td>2 (11.11)</td>
<td>-</td>
</tr>
<tr>
<td>Chronic cardiovascular and cerebrovascular disease (including hypertension and CHD)</td>
<td>4 (14.3)</td>
<td>3 (16.7)</td>
<td>-</td>
</tr>
<tr>
<td>Chronic pulmonary disease (including COPD and asthma)</td>
<td>1 (1.36)</td>
<td>1 (5.5)</td>
<td>-</td>
</tr>
<tr>
<td>Chronic liver disease (including chronic hepatitis B and cirrhosis)</td>
<td>2 (7.1)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Chronic renal disease</td>
<td>1</td>
<td>1 (5.5)</td>
<td>-</td>
</tr>
</tbody>
</table>

CHD: Coronary heart disease, COPD: Chronic obstructive pulmonary disease
Incidence of cancer among COVID-19 patients

Eight studies have specified the number of cancer patients being infected in the COVID-19 pandemic. The results are summarized in Table 2.

Single-institutional studies from China like that of Huang et al.,[12] Chen et al.,[13] Wang et al.,[14] and Wu et al.[16] have reported the incidence of cancer among the various other COVID-19-positive cases.

Distribution of various cancers

The studies which looked into the distribution of various cancers among the COVID-19 patients are summarized in Table 3.

Among the several sites of cancer in the study by Zhang et al.,[9] lung (25%, n = 7) was the most common site, and it was observed that symptoms of dyspnea occurred much earlier in cancer patients compared to that in the general population (1.0 [0.0–3.5] vs. 8.0 [5.0–13.0] days) and other cancer patients (1.0 [0.0–3.5] vs. 5.0 [4.0–7.0] days).

Lung was also the most frequent site (28% n = 5) in the study by Liang et al.,[10] however, compared to other sites, patients with lung cancer (1/5, 20% vs. 8/13, 62%) did not have much likelihood of developing severe events.

Treatment history

The treatment protocol among the various studies was according to their institutional protocols. Detailed treatment history was not available in all the studies. Table 4 summarizes the antitumoral treatment history received by patients across the various studies.

Staging of the tumor was presented only in the study by Zhang et al.[9] where 18 (64.3%) patients were in Stages I–III and 10 (35.7%) patients in Stage IV disease. On descriptive analysis, it was found that 70% (7/10) of Stage IV cancer patients had developed severe events, whereas only 44.4% of the rest had such events with no statistically significant association on univariate analysis. The tumor stage could not be included in multivariate cox model analysis due to a high correlation between stage and the antitumor treatment within 14 days (correlation coefficient r = −0.518, P = 0.005).

In the study by Zhang et al.,[9] the patients receiving antitumoral treatment within 2 weeks, 5 (83%), developed severe events.

Multivariate analysis adjusted for gender and age revealed that those patients who received antitumor treatment within 2 weeks before COVID-19 infection had a greater risk of developing severe events with marginal statistical significance (HR: 4.079, 95% CI: 1.086–15.322; P = 0.037).

Nearly 75% of the patients (3/4) who underwent surgery or chemotherapy in the previous month had a high risk of developing clinically severe events than those (6/14) not receiving chemotherapy or surgery in the study by Liang et al.[10] It was additionally confirmed by logistic regression (odds ratio [OR]: 5.34, 95% CI: 1.80–16.18; P = 0.0026) after adjusting for other risk factors such as smoking, age, and other comorbidities.

In the study by Yu et al.,[11] fewer than half of these COVID-19 patients were undergoing active treatment for malignancy.

Morbidity and mortality in cancer patients

According to the study by Zhang et al.,[9] out of the 28 cancer patients, 53.6% of the patients advanced to severe events, 21.4% required ICU admission, 35.7% had life-threatening complications, and 28.6% of the patients succumbed to death. The cause of death encompassed...
acute respiratory distress syndrome (ARDS) in about 62.5% (5/8), pulmonary embolism in 12.5% (1/8), septic shock in 12.5% (1/8), and acute myocardial infection in 12.5% (1/8) of patients.

On multivariate analysis for the risk of developing severe events, there was no statistically significant correlation with age (HR: 1.455; 95% CI: 0.478–4.430; \( P = 0.509 \)) and gender (HR: 0.574; 95% CI: 0.162–2.038; \( P = 0.390 \)).

Liang et al.[10] used Cox regression model to estimate the time-dependent hazards of progressing to severe events, and it was seen that cancer patients deteriorated more rapidly (median time to severe event – 13 days) (interquartile range: 6–15) than those without cancers (median time to severe event – 43 days) (20 – not reached), \( P < 0.0001 \), HR: 3.56, 95% CI: 1.65–7.69, after adjusting for age.

The only risk factor for developing severe events in the study by Liang et al.[10] was found to be old age (OR: 1.43, 95% CI: 0.97–2.12; \( P = 0.072 \)). When comorbidities such as hypertension (OR: 1.878, 95% CI: 1.217–2.898; \( P = 0.004 \)), chronic obstructive pulmonary disease (COPD) (OR: 3.397, 95% CI: 1.373–8.409; \( P = 0.008 \)), and diabetes mellitus (OR: 2.206, 95% CI: 1.331–3.656; \( P = 0.002 \)) were not associated with the risk of developing severe events.

In a case series by Grasselli et al.,[19] the demographic details of COVID-19 patients admitted to ICUs in Lombardy, Italy, were gathered telephonically by the ICU network team. Data were collected from February to March 18, 2020. Among 1591 patients requiring admission into ICU, 81 had a history of malignancy either in active or remission stage, with 69 of those patients above 60 years.

In a large case series of 72,314 patients published by the Chinese CDC,[18] the overall case fatality was around 2.3% and in patients with a history of malignancy, it was 5.6%.

The WHO China Joint Mission on COVID-19 reported a case fatality rate of 7.6% for cancer.

Onder et al.[20] analyzed a subsample of 355 patients who died due to COVID-19 in Italy. The mean age was found to be 79.5 years (standard deviation 8.1) and 72 patients died due to cancer, leading to a case fatality rate of 20.3%.

### Biological basis of susceptibility

Cancer patients are more susceptible to infection due to their immunocompromised status owing to multiple reasons such as the disease itself, malnutrition, postsurgical status, or the anticancer treatment that they receive.

In a review article by Galluzzi et al.[21] they have reported that as tumors evolve, they favor the release of myeloid-derived suppressor cells (MDSCs) from the bone marrow, which exerts immunosuppressive effects both intratumorally and systemically. In addition, myelosuppression due to cytotoxic chemotherapy or early phase of hematopoietic stem cell transfer, conventional chemotherapy, and targeted therapy drugs such as rituximab may alter both humoral and T-cell-mediated immunity, making the individual more susceptible to COVID-19.

Cai[22] analyzed transcriptomic databases of lung tissue and found that smoking tobacco increases the gene expression of ACE2 in the lung, which is also the binding receptor for COVID-19. This could explain the reason for smokers being susceptible to COVID-19 as they both share the same receptor.

Malnutrition in a cancer patient can be due to multiple reasons such as nausea and vomiting because of chemotherapeutic drugs, loss of appetite, the morbidity associated with surgery, or long-term hospitalization. Moreover, 20%–80% of cancer patients become malnourished during their clinical course.[23–25] This can adversely affect the immunity of a patient, making him/her more prone to infection by respiratory pathogens.

In the study by Zhang et al.,[9] lung cancer patients showed reduced lung volume due to tumor co-existing with features of pneumonia.

### Quality of life

Quality-of-life assessment is a multidimensional paradigm measuring subjective assessment of well-being and health status including both mental and physical health. A qualitative survey was done by Casanova et al.[24] in the Milan focal point of Italy on young cancer patients during COVID-19 in order to assess their level of stress. According to the survey, it was found that a relatively large proportion of these patients felt themselves to be at risk of severe complications. A semi-structured questionnaire was developed by a committee consisting of Youth Project’s staff (psychologists and physicians) and was later approved.

---

**Table 4: Antitumoral treatment details of COVID-19-positive cancer patients**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Zhang et al.[9] (n=28), n (%)</th>
<th>Liang et al.[10] (n=18), n (%)</th>
<th>Yu et al.[11] (n=12), n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery</td>
<td>21 (75.0)</td>
<td>13 (72.2)</td>
<td>1 (8.3)</td>
</tr>
<tr>
<td>Chemo/radiotherapy</td>
<td>25 (89.3)</td>
<td>9 (50)</td>
<td>7 (58.3)</td>
</tr>
<tr>
<td>Target/immunotherapy</td>
<td>6 (21.4)</td>
<td>3 (16.7)</td>
<td>1 (8.3)</td>
</tr>
<tr>
<td>Best supportive care</td>
<td>-</td>
<td>-</td>
<td>4 (33.3)</td>
</tr>
<tr>
<td>Details not available</td>
<td>-</td>
<td>1 (5.6)</td>
<td>1 (8.3)</td>
</tr>
</tbody>
</table>
Smoking can lead to lung cancer and COPD and increase susceptibility to acquiring COVID-19. Although smoking was predominantly more among cancer groups in the study by Liang et al.,\textsuperscript{[10]} it failed to establish any statistical significance.

Males were more than females among all studies with mean age ranging from 63 to 66 years, implying elderly age group being affected. Elderly individuals had the risk of progressing to severe events.

Cardiovascular diseases and diabetes were among the most prevalent comorbidities. A systematic review and meta-analysis by Emami et al.\textsuperscript{[31]} has summarized that cardiovascular diseases, hypertension, COPD, and chronic kidney disease were among the most prevalent underlying comorbidities in hospitalized COVID-19 patients, which is similar to our findings in cancer patients.

Metabolic syndrome-related health conditions such as hypertension, cardiovascular diseases, and diabetes are known to downregulate innate immunity in the host. However, in the study by Liang et al.,\textsuperscript{[10]} progression to severe events was not related to comorbidities. Given that COVID-19 has a relatively protracted incubation period and during this phase, the infected person can transmit the virus to another without being symptomatic, it is strongly recommended that elderly cancer patients with chronic or underlying diseases avoid close contact with others in the community, especially in areas where the epidemic is rampant.

Findings of ground-glass opacity and patchy consolidation on CT scan of cancer patients were similar to overall COVID-19 infected patients.\textsuperscript{[33]} The role of systemic steroids is controversial in viral pneumonia, as it is thought to be an immunosuppressant. However, it failed to demonstrate any benefit in reducing the incidence of severe events.\textsuperscript{[9]}

In their study, cancer patients who had ongoing treatment or those who had completed treatment within the past month were at risk of developing clinical severe events such as ICU admissions, mechanical ventilation, or death. Zhang et al.\textsuperscript{[9]} reported 53.6% of cancer patients developing severe events, whereas Liang et al.\textsuperscript{[10]} had only 39% of people developing severe events. This discrepancy is due to the following reasons:

1. The definition of severe events by both groups was different: Zhang et al.\textsuperscript{[9]} included ICU admission or mechanical ventilation or death, whereas Liang et al.\textsuperscript{[10]} defined it as ICU admission or invasive ventilation or death, narrowing the cohort to only those requiring invasive ventilation

2. Zhang et al.\textsuperscript{[9]} included cases from Wuhan, whereas Liang et al.\textsuperscript{[10]} included patients from the entire nation. Wuhan, on the other hand, had to face a dire shortage of resources due to the sudden outbreak and delay in delivering health facilities, leading to an increase in mortality.

The study by Grasselli et al.\textsuperscript{[19]} had many limitations as newly setup ICUs were not included, it was telephonic data...
Death was seen in 28.6% of the patients who developed critical events in the study by Zhang et al.\textsuperscript{[9]} In comparison to the general COVID-19 population, 5% reached clinically critical status, and the case fatality was nearly half (49%).\textsuperscript{[13]} Studies from China reported a case fatality of 5.6%–7.6%, whereas Onder et al.\textsuperscript{[20]} from Italy reported a case fatality rate of 20.3%. It is also to be considered that a large proportion of people were aged 90 or above in Italy, and this group has a very high case fatality rate (22.7%).

Zhang et al.\textsuperscript{[9]} reported that 28.6% of patients developed COVID-19 infection during hospital admission suspecting nosocomial transmission. Nosocomial transmission is reported by Wang et al.\textsuperscript{[14]} to be around 41%. Cancer patients can acquire infections in hospitals during their course of anticancer treatment. This emphasizes vigorous screening and isolation of suspected patients at cancer centers. Precautionary measures should also extend to the family members and the health-care personnel attending such patients to prevent infection and transmission. The European Society for Medical Oncology recommends a tiered approach according to the priority of intervention required, and also the benefit/risk ratio, prognosis, patient preferences, and comorbidities should be taken into consideration.

While navigating through all these, an epidemic like COVID-19 has made their condition even worse as the medical facilities are likely to be jeopardized due to the overwhelming patients. Life in a pandemic is more disturbing due to social distancing, isolation, lockdown, and fear of contracting infections, which lead to a cycle of concern, worry, and mental agony. There are also groundless fears due to the fabricated news and information circulated in social media. Delays in treatment may lead to fear of death, progression, or recurrence in cancer patients.

Thus, the following points have to be borne in mind while managing cancer patients:

1. At present, there is no direct evidence to support withholding anti-tumor therapy. Treatment that is likely to worsen the immune status of a patient should be postponed or modified
2. Patients should be triaged according to type and stage of cancer and need for aggressive treatment
3. The possible benefits and risks of infection have to be discussed with the patient and family members. If continuing treatment is the need of the hour, then patients should be guided accordingly
4. The diagnosis of cancer itself has a lot of psychosocial impact on a person. The journey from diagnosis to treatment can affect relationships, finances, and the physical and mental health of a person
5. Telemedicine can help in reaching many patients and decrease anxiety. Cancer patients require follow-ups at regular intervals in order to treat early recurrence, to detect new primaries, or for rehabilitation. Due to lockdown, asymptomatic patients can be followed up telephonically. Any new symptoms or concerns can be dealt, and the necessary solutions can be discussed

6. In certain parts of the country wherein there is no access to oncology facilities, the referral centers can utilize tele-expertise.

Studies have shown that cancer patients have worse outcomes from COVID-19, providing a reason to pay more timely attention to cancer patients in case they deteriorate rapidly. As a result, more intensive surveillance should be considered when cancer patients acquire COVID-19, especially elderly, patients with comorbidities, and patients receiving ongoing treatment. Further prospective studies from different parts of the world with a large sample size are warranted to validate the findings. More robust evidence is required to address various factors such as screening, prevention, quality of life, and treatment modalities.

**Conclusion**

Cancer patients with COVID-19 have worse outcomes compared to the general population therefore should undergo vigorous screening and intensive surveillance. Anticancer treatment during COVID19 should be altered according to the type and prognosis of cancer.

**Limitations**

1. Due to the recent outbreak of the virus, most of the studies do not have the follow-up data pertaining to the infection, the values of which are crude and may change the mortality pattern
2. The possible benefits and risks of infection have to be discussed with the patient and family members. If continuing treatment is the need of the hour, then patients should be guided accordingly
3. Tumor types were diverse and staging was not included among the various cancers
4. Continued surveillance and accurate reporting of demographics, testing policies, and treatment outcomes is necessary from different places across the globe for better understanding and treatment planning.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**
